Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MUX | Ann: Appendix 3Y | 10/08/15 | 2 | 2.4K | |||
|
|||||||
MUX | Ann: Appendix 3Y | 07/08/15 | 0 | 867 | |||
|
|||||||
MUX | Ann: Appendix 3Y | 07/08/15 | 0 | 677 | |||
|
|||||||
MUX | Ann: Appendix 3B Placement Shares | 07/08/15 | 0 | 734 | |||
|
|||||||
MUX | Ann: Appendix 3B Performance Rights | 07/08/15 | 0 | 765 | |||
|
|||||||
MUX | Ann: Company Name Change | 07/08/15 | 0 | 1.2K | |||
|
|||||||
MUX | Ann: Cleansing Statement | 07/08/15 | 0 | 576 | |||
|
|||||||
MUX | Ann: Beer&Co Research Report | 05/08/15 | 0 | 787 | |||
|
See All Discussions